MedTrace Logo

Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant Chemoradiotherapy

NCT06061263 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2023-09-29

No results posted yet for this study

Summary

It has been reported that patients with esophageal squamous cell carcinoma who achieved pathological complete response (PCR) to neoadjuvant chemoradiotherapy have better survival than those with non-PCR. Howeve, there is still recurrent diseases developed in PCR patients after esophagectomy. Herein, we aimed to investgate the risk factors of recurrence in PCR patients.

Conditions

  • Esophageal Cancer

Interventions

OTHER

follow up

collecttion of clinicopathological data from a prespectively collected databse, including survival data.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-06-30
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06061263 on ClinicalTrials.gov